Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Author’s Reply

Value in Health(2021)10.1016/j.jval.2020.12.025Source: DataRank Database

Author’s Reply is a research paper published in Value in Health (2021). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.00)OA: bronzeTopics (18)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Ashley L. Cole ORCID,Ashley A. Leech ORCID,William A. Wood ORCID,Stacie B. Dusetzina ORCID,Joehl T. Nguyen

Live enrichment

PubMed:34243833 OpenAlex:https://openalex.org/W4205966865

Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill

Grant: T32-HS000032

University of North Carolina at Chapel Hill

Grant: T32LM012420-03

NLM NIH HHS

Grant: T32 LM012420

AHRQ HHS

Grant: T32 HS000032

Arnold Ventures

Agency for Healthcare Research and Quality

National Institutes of Health

Bristol-Myers Squibb

Leukemia and Lymphoma Society

Commonwealth Fund

GlaxoSmithKline

American Foundation for Pharmaceutical Education

FWCI

0.00

Citation Percentile

0.2%

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.valueinhealthjournal.com/article/S1098301521001613/pdf

publisherhttp://www.valueinhealthjournal.com/article/S1098301521001613/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1098301521001613?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1098301521001613?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jval.2020.12.025

Fields of Study

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchEosinophilic Disorders and SyndromesCost-Benefit AnalysisHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase Inhibitors

MeSH Terms

Cost-Benefit AnalysisHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase Inhibitors

Keywords

ImatinibMyeloid leukemiaContext (archaeology)ScopusTyrosine-kinase inhibitorTyrosine kinaseDisease